Bortezomib
- PDF / 123,172 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 58 Downloads / 175 Views
1
S
Renal failure: case report A 62-year-old man developed severe renal failure while receiving bortezomib for treatment-resistant multiple myeloma; he subsequently died. The man started receiving a 3-weekly regimen of bortezomib at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, followed by a rest for 10 days. After the first bortezomib dose, a slight increase in his serum creatinine level was noticed. The man started to receive corticosteroids and hydration. However, his serum creatinine and blood urea nitrogen (BUN) levels continued to increase with administration of the next three bortezomib doses; his creatinine levels were 165, 420 and 588 µmol/L, and his BUN levels were 12.9, 15.5 and 23.8 mmol/L, respectively. His renal function promptly deteriorated. He developed oliguria, hyperkalaemia (5.6 mmol/L), hypocalcaemia (1.8 mmol/L) and hyperphosphataemia (2.4 mmol/L). He was admitted to a nephrology department and started to receive dialysis three times weekly. He had elevated markers of tubular damage (Nacetylglutamate, alanine aminopeptidase and γglutamyltransferase). From day to day, his clinical condition had been worsening. He had extreme prostration and paroxysmal tachycardia. Within 1 month, he died. Stankovic S. Severe acute renal failure as a result of tumor lysis syndrome after bortezomib therapy in a case of therapy-resistant multiple myeloma. Haematologica 92 (Suppl. 1): 544 abstr. 1539, Jun 2007 [abstract] 801093815 Macedonia
0114-9954/10/1170-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 22 Sep 2007 No. 1170
Data Loading...
